Skip to Content

Oxybutynin Disease Interactions

There are 6 disease interactions with oxybutynin:

Major

Anticholinergics (applies to oxybutynin) autonomic neuropathy

Major Potential Hazard, Moderate plausibility.

Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males. Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.

References

  1. "Product Information. Atropine Sulfate Injection, USP (atropine)." ESI Lederle Generics, Philadelphia, PA.
Major

Antiperistaltic agents (applies to oxybutynin) infectious diarrhea

Major Potential Hazard, Low plausibility. Applicable conditions: Infectious Diarrhea/Enterocolitis/Gastroenteritis

The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria. These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics. Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged. In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool. Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.

References

  1. "Product Information. Atropine Sulfate Injection, USP (atropine)." ESI Lederle Generics, Philadelphia, PA.
  2. Marshall WF Jr, Rosenthal P, Merritt RJ "Atropine therapy and paralytic ileus in an infant." J Pediatr Gastroenterol Nutr 9 (1989): 532-4
  3. "Product Information. Imodium (loperamide)." Janssen Pharmaceutica, Titusville, NJ.
  4. "Lomotil for diarrhea in children." Med Lett Drugs Ther 17 (1975): 104
  5. Walley T, Milson D "Loperamide related toxic megacolon in Clostridium difficile colitis." Postgrad Med J 66 (1990): 582
  6. Brown JW "Toxic megacolon associated with loperamide therapy." JAMA 241 (1979): 501-2
View all 6 references
Major

Oxybutynin (applies to oxybutynin) angle-closure glaucoma

Major Potential Hazard, High plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

The use of oxybutynin is contraindicated in patients with uncontrolled angle-closure (narrow angle) or narrow anterior chamber glaucoma. Oxybutynin exerts anticholinergic activity (1/5 that of atropine) and can result in increased intraocular pressure and loss of accommodation.

References

  1. "Product Information. Ditropan (oxybutynin)." Hoechst Marion-Roussel Inc, Kansas City, MO.
Major

Oxybutynin (applies to oxybutynin) GI/urinary obstruction/atony

Major Potential Hazard, High plausibility. Applicable conditions: Inflammatory Bowel Disease, Urinary Retention, Gastrointestinal Obstruction

The use of oxybutynin is contraindicated in patients with GI obstruction, ileus, atony, megacolon, toxic megacolon associated with ulcerative colitis, severe colitis, and obstructive uropathy. Oxybutynin exerts direct antispasmodic effects on smooth muscles and possesses anticholinergic activity (1/5 that of atropine).

References

  1. "Product Information. Ditropan (oxybutynin)." Hoechst Marion-Roussel Inc, Kansas City, MO.
Major

Oxybutynin (applies to oxybutynin) myasthenia gravis

Major Potential Hazard, High plausibility.

The use of oxybutynin is contraindicated in patients with myasthenia gravis. Oxybutynin exerts direct antispasmodic effects on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle (1/5 the anticholinergic activity of atropine).

References

  1. "Product Information. Ditropan (oxybutynin)." Hoechst Marion-Roussel Inc, Kansas City, MO.
Moderate

Oxybutynin (applies to oxybutynin) central nervous system

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Dementia, CNS Disorder

Oxybutynin is associated with anticholinergic central nervous system (CNS) effects. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered. Oxybutynin should be used with caution in patients with Parkinson's disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.

Oxybutynin drug interactions

There are 249 drug interactions with oxybutynin

Oxybutynin alcohol/food interactions

There is 1 alcohol/food interaction with oxybutynin

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.